Preliminary estimates of the consolidated financial data for 2024 and the Management Board's recommendation regarding the allocation of the Company's 2024 profit

Date: 22 April 2025

Subject: Preliminary estimates of the consolidated financial data for 2024 and the Management Board’s recommendation regarding the allocation of the Company’s 2024 profit

Legal basis: Article 17(1) of MAR – Inside information

Text of the report:

The Management Board of Diagnostyka S.A. (the “Company”, the “Issuer”) publishes, attached as an appendix to this Report, selected preliminary financial data for 2024.

The final financial figures for 2024 will be provided in the separate and consolidated full-year reports, scheduled for publication on 24 April 2025.

The Company’s Management Board further announces that on 22 April 2025 it resolved to recommend to the Supervisory Board and the General Meeting the following allocation of the Company’s profit for 2024 of PLN 198,207,885.91:

• PLN 111,734,015.00 to be distributed as dividend of PLN 3.31 per share;
• the balance of PLN 86,473,870.91 to be transferred to the Company’s statutory reserve funds.

The dividend payout ratio is 50.03% of the amount disclosed in the Group’s financial statements under net profit attributable to owners of the parent, based on the Group’s preliminary estimates.

The Company’s governing body competent to resolve on the allocation of profit, including dividend payment, is the General Meeting.

Specific legal basis: Article 17(1) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/82/EC (OJ L 173) (“MAR”).

For the Company:

Paweł Chytła – Vice President of the Management Board

Dariusz Zowczak – Vice President of the Management Board